[go: up one dir, main page]

HN2009001268A - Compuestos [1,2,3] - benzotriazinona sustituido en 3 para incrementar las respuestas sinapticas glutamatergicas - Google Patents

Compuestos [1,2,3] - benzotriazinona sustituido en 3 para incrementar las respuestas sinapticas glutamatergicas

Info

Publication number
HN2009001268A
HN2009001268A HN2009001268A HN2009001268A HN2009001268A HN 2009001268 A HN2009001268 A HN 2009001268A HN 2009001268 A HN2009001268 A HN 2009001268A HN 2009001268 A HN2009001268 A HN 2009001268A HN 2009001268 A HN2009001268 A HN 2009001268A
Authority
HN
Honduras
Prior art keywords
glutamatergical
benzotriazinona
compounds
replaced
increase
Prior art date
Application number
HN2009001268A
Other languages
English (en)
Inventor
Cordi Alexis
Rogers Gary
Mueller Rudolf
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of HN2009001268A publication Critical patent/HN2009001268A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

ESTA INVENCIÓN SE REFIERE A UN COMPUESTO Y COMPOSICIONES FARMACÉUTICAS DE FORMULA: VER REIVINDICACIÓN 1
HN2009001268A 2007-01-03 2009-07-03 Compuestos [1,2,3] - benzotriazinona sustituido en 3 para incrementar las respuestas sinapticas glutamatergicas HN2009001268A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87850307P 2007-01-03 2007-01-03
US92143307P 2007-04-02 2007-04-02

Publications (1)

Publication Number Publication Date
HN2009001268A true HN2009001268A (es) 2011-12-27

Family

ID=39608956

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2009001268A HN2009001268A (es) 2007-01-03 2009-07-03 Compuestos [1,2,3] - benzotriazinona sustituido en 3 para incrementar las respuestas sinapticas glutamatergicas

Country Status (37)

Country Link
US (1) US8173644B2 (es)
EP (1) EP2144506B1 (es)
JP (1) JP5139446B2 (es)
CN (1) CN101616592B (es)
AP (1) AP2502A (es)
AR (1) AR064740A1 (es)
AT (1) ATE527269T1 (es)
AU (1) AU2007342365B2 (es)
BR (1) BRPI0720749A2 (es)
CA (1) CA2674460C (es)
CR (1) CR10906A (es)
CU (1) CU23804B7 (es)
CY (1) CY1112493T1 (es)
DK (1) DK2144506T3 (es)
EA (1) EA017437B1 (es)
EC (1) ECSP099499A (es)
ES (1) ES2374995T3 (es)
GE (1) GEP20125438B (es)
GT (1) GT200900189A (es)
HN (1) HN2009001268A (es)
HR (1) HRP20110970T1 (es)
IL (1) IL199651A (es)
MA (1) MA31160B1 (es)
ME (1) ME00819B (es)
MX (1) MX2009007242A (es)
MY (1) MY154877A (es)
NI (1) NI200900131A (es)
NZ (1) NZ578293A (es)
PL (1) PL2144506T3 (es)
PT (1) PT2144506E (es)
RS (1) RS52108B (es)
SG (1) SG163545A1 (es)
SI (1) SI2144506T1 (es)
SV (1) SV2009003322A (es)
TN (1) TN2009000277A1 (es)
WO (1) WO2008085506A1 (es)
ZA (1) ZA200904826B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114158B1 (en) * 2007-01-03 2012-08-08 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
CN101742911A (zh) 2007-05-17 2010-06-16 科泰克斯药品公司 用于增强谷氨酸能突触反应的二取代的酰胺
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
BRPI0823262A2 (pt) 2007-08-10 2013-09-24 Cortex Pharma Inc mÉtodo de tratamento de depressço respiratària e uso de um composto na fabricaÇço de um medicamento para o tratamento de depressço respiratària
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
US9242938B2 (en) 2011-11-22 2016-01-26 Beijing Medisan Technology Co., Ltd Glycine reuptake inhibitor and use thereof
FR3019464B1 (fr) * 2014-04-07 2016-05-06 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
FR3034019B1 (fr) 2015-03-26 2017-03-17 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
CA2988572A1 (en) * 2015-06-26 2016-12-29 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
CN106226509B (zh) * 2016-08-12 2019-09-06 中国人民解放军第四军医大学 一种在小鼠前扣带回皮层诱发dse现象的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723436A (en) 1971-02-25 1973-03-27 Sun Oil Co Process for aromatic lactams
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
FR2597103B1 (fr) 1986-04-15 1988-12-16 Provesan Sa Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde
PT651746E (pt) 1992-07-24 2002-09-30 Univ California Drogas que intensificam as respostas sinapticas mediadas por receptores de ampa
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
EP0709384B1 (de) * 1994-10-31 1998-12-23 MERCK PATENT GmbH Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren
US5650409A (en) 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US6030968A (en) 1996-09-17 2000-02-29 The Regents Of The University Of California Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
HUP0101280A3 (en) 1998-02-18 2003-02-28 Neurosearch As Positive ampa receptor modulator compounds and their use
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6303542B1 (en) * 2000-08-18 2001-10-16 Rohm And Haas Company Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones
UA79940C2 (en) * 2001-11-26 2007-08-10 Cortex Pharma Inc Carbonylbenzoxazine compounds for enhancing of glutamatergic synaptic responses
JP2003238555A (ja) * 2002-02-20 2003-08-27 Sumitomo Pharmaceut Co Ltd 細胞死抑制剤
AUPS255202A0 (en) * 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
JP2006516283A (ja) * 2003-01-13 2006-06-29 コーテックス ファーマシューティカルズ， インコーポレイテッド 睡眠不足とストレスに起因する知覚衰退の処置方法
GB0317482D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
EP2114158B1 (en) 2007-01-03 2012-08-08 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
CN101742911A (zh) 2007-05-17 2010-06-16 科泰克斯药品公司 用于增强谷氨酸能突触反应的二取代的酰胺
BRPI0823262A2 (pt) 2007-08-10 2013-09-24 Cortex Pharma Inc mÉtodo de tratamento de depressço respiratària e uso de um composto na fabricaÇço de um medicamento para o tratamento de depressço respiratària
CN101801939A (zh) * 2007-09-20 2010-08-11 科泰克斯药品公司 用于增强谷氨酸能突触反应的3-取代1,2,3-三嗪-4-酮类和3-取代1,3-嘧啶酮类

Also Published As

Publication number Publication date
MX2009007242A (es) 2009-09-02
BRPI0720749A2 (pt) 2014-01-14
ME00819B (me) 2012-03-20
JP2010514838A (ja) 2010-05-06
DK2144506T3 (da) 2012-03-05
JP5139446B2 (ja) 2013-02-06
SI2144506T1 (sl) 2012-01-31
HK1140105A1 (en) 2010-10-08
ECSP099499A (es) 2009-10-30
AP2009004931A0 (en) 2009-08-31
PL2144506T3 (pl) 2012-04-30
AR064740A1 (es) 2009-04-22
GT200900189A (es) 2011-08-02
NZ578293A (en) 2012-01-12
CY1112493T1 (el) 2015-12-09
CU23804B7 (es) 2012-03-15
AU2007342365B2 (en) 2012-11-15
AU2007342365A1 (en) 2008-07-17
CN101616592A (zh) 2009-12-30
PT2144506E (pt) 2011-12-21
IL199651A0 (en) 2010-04-15
AP2502A (en) 2012-10-23
SV2009003322A (es) 2010-02-05
NI200900131A (es) 2010-03-11
US20100137295A1 (en) 2010-06-03
US8173644B2 (en) 2012-05-08
MA31160B1 (fr) 2010-02-01
CA2674460C (en) 2014-07-15
GEP20125438B (en) 2012-03-26
ATE527269T1 (de) 2011-10-15
CA2674460A1 (en) 2008-07-17
IL199651A (en) 2015-08-31
TN2009000277A1 (en) 2010-10-18
EP2144506B1 (en) 2011-10-05
SG163545A1 (en) 2010-08-30
EP2144506A1 (en) 2010-01-20
EA200900925A1 (ru) 2009-12-30
EP2144506A4 (en) 2010-05-05
ES2374995T3 (es) 2012-02-23
RS52108B (sr) 2012-08-31
CU20090117A7 (es) 2011-10-05
HRP20110970T1 (hr) 2012-01-31
WO2008085506A1 (en) 2008-07-17
MY154877A (en) 2015-08-14
EA017437B1 (ru) 2012-12-28
ZA200904826B (en) 2010-09-29
CN101616592B (zh) 2013-06-05
CR10906A (es) 2009-10-23

Similar Documents

Publication Publication Date Title
HN2009001268A (es) Compuestos [1,2,3] - benzotriazinona sustituido en 3 para incrementar las respuestas sinapticas glutamatergicas
CY1123777T1 (el) Συνθετικο ενδιαμεσο χρησιμο στην παρασκευη αναστολεων c-met τριαζολοπυριδινης
CR11373A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA
DK2144618T3 (da) Bioeffektive krill-olie-sammensætninger
MA32551B1 (fr) Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires
BRPI0922354A2 (pt) composições lubrificantes antimicrobianas
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
SV2010003472A (es) Compuestos de pirazol
BRPI0821731A2 (pt) Composições cosméticas para conceder flimes superhidrofóbicos
BRPI0920276A2 (pt) várias composições para exclusão de exon dmd
CR11454A (es) Derivados de isoxazolo-piridina
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
PA8851501A1 (es) Compuestos purina
MA32142B1 (fr) Forme cristalline de dérivés de phénylamino pyrimidine
CU20090139A7 (es) Nuevo procedimiento de síntesis de agomelatina
AR062211A1 (es) Derivados de 6-carboxi-normorfinano. composiciones farmaceuticas
EP2376612A4 (en) OIL COMPOSITIONS
BRPI0819566A2 (pt) "composições antissépticas para tecidos"
EA201101675A1 (ru) Спироэпоксиды как промежуточные продукты синтеза
PT2205720T (pt) Composições para tratamento de esclerose múltipla
CU20090137A7 (es) Nuevo procedimiento de síntesis de la agomelatina
BRPI0916566B8 (pt) isonicotinamida fenilamina, seu uso, composição farmacêutica, e kit
GT200600117A (es) Nuevos compuestos farmaceuticos